Global Initiative for Chronic Obstructive Lung Disease 2023 Report: GOLD Executive Summary
Why is this work in the frame?
A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.
Machine scores (provisional)
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
- Teacher spread
- 0.291 · how far apart the two teachers sit on this one work
- Validation status
score_only:v0-immature-baseline· verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it
Abstract
<b>Executive summary of the Global Strategy for Prevention, Diagnosis and Management of COPD 2023: the latest evidence-based strategy document from the Global Initiative for Chronic Obstructive Lung Disease (GOLD</b><b>)</b> https://bit.ly/3KCaTGe
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
The record
- Venue
- European Respiratory Journal
- Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Field
- Medicine
- Canadian institutions
- St. Paul's HospitalUniversity of British ColumbiaMcGill University Health Centre
- Funders
- National Institutes of HealthAgenzia Italiana del Farmaco, Ministero della SaluteCanadian Institutes of Health ResearchSunovionAstraZenecaCSL BehringChiesi FarmaceuticiSanofiAmerican Thoracic SocietyPfizerCOPD FoundationGlaxoSmithKlineRegeneron PharmaceuticalsTeva Pharmaceutical Industries
- Keywords
- MedicineObstructive lung diseaseCOPDLung diseaseExecutive summaryPulmonary diseaseGold standard (test)Intensive care medicineLungInternal medicineFinance
- Has abstract in OpenAlex
- yes